Acute myeloid leukaemia is an aggressive form of blood cancer, where only about 20% of patients are expected to survive for 5 or more years after diagnosis. A new drug called midostaurin can triple survival times for some patients and is now available on the NHS. However, only a subgroup of Acute myeloid leukaemia patients (~30%) are eligible to receive this treatment and approximately 50% of those will experience no benefit; therefore, only about 15% of Acute myeloid leukaemia patients overall actually benefit from treatment.
Consequently, many patients are exposed to unnecessary side-effects, are denied the opportunity to be recruited on trials for drugs that may be effective, and the NHS are subjected to unnecessary costs of treating patients that fail to benefit.
Kinomica have used KScan®, a much more accurate way to predict whether an Acute myeloid leukaemia patient will respond to midostaurin. KScan® involves measuring the simultaneous activity of kinases within a patient’s cancer cells. This readout can then better predict whether midostaurin will destroy those cells.